Abstract
Introduction: The outbreak of Coronavirus 2019 (COVID-19) has spread rapidly across the globe and has become a global pandemic. Many treatments are being studied, of which interleukin 6 inhibition is an effective method.
Case report: Fourcases of patients confirmed covid-19 by PCR method, being treated at COVID-19 Intensive Care Center of Hue Central Hospital in Ho Chi Minh city, severe pneumonia requires ventilation assistance. The patients were treated with a regimen including Tocilizumab that resulted in increased interleukin 6 results after 1 week of treatment.
Conclusion: In a clinical trial involving patients with severe pneumonia caused by Covid-19, it was found that Interleukin 6 increased after 1 week of treatment.
References
Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2:e594-602.
Braun GS, Nagayama Y, Maruta Y, et al. IL - 6 Trans - Signaling Drives Murine Crescentic GN. J Am Soc Nephrol. 2016;27(1):132-142.
Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473-4.
Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Trans Med. 2020;18:406.
Jones SA, Jenkins BJ. Recent insights into targeting the IL - 6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018 Dec;18(12):773-789.
Martínez Sanz J, Muriel A, Ron R, Herrera S, Pérez Molina JA, Moreno S, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID 19: a multicentre cohort study. Clin Microbiol Infect. 2021;27(2):238-43.
Kewan T, Covut F, Al Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study. EClinicalMedicine. 2020;24:1-8.
Kang S, Tanaka T, Inoue H, et al. IL - 6 trans - signaling induces plasminogen activator inhibitor - 1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci U S A. 2020;117(36):22351-22356.
| Published | 01-01-2022 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 75 (2022) | |
| Section | Case report | |
| DOI | 10.38103/jcmhch.2022.75.6 | |
| Keywords | Interleukin 6, Tocilizumab, Covid-19. Interleukin 6, Tocilizumab, Covid-19 |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2022 Journal of Clinical Medicine Hue Central Hospital